Bayer Korea Divests OTC Oral Contraceptives To Gain Merck’s Market-Leading Brand
This article was originally published in The Tan Sheet
Executive Summary
In the first move by a South Korean pharma to acquire global brand drugs, Dong-A Pharm takes over four oral contraceptive products from Bayer Korea to beef up its OTC business and female product portfolios. Bayer Korea, meanwhile, turns its acquisition sights on MSD Korea’s market-leading Mercilon.
You may also be interested in...
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
OliX Diversifies Into mRNA Amid Growing Global Interest
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: